Kidney Disease and Heart Health: A Deadly Connection
- Researchers at UVA Health and Mount Sinai have identified a substance released by damaged kidneys that directly contributes to heart failure, explaining why heart-related complications are the leading...
- Damaged kidneys release a substance into the bloodstream that triggers cardiac fibrosis - the thickening and scarring of heart tissue - directly harming the heart.
- Definition / Direct Answer Cardiac fibrosis, induced by factors released from failing kidneys, is a key mechanism driving heart failure in patients with chronic kidney disease.
“`html
Chronic Kidney Disease and Heart Failure: A newly Identified Link
Table of Contents
Researchers at UVA Health and Mount Sinai have identified a substance released by damaged kidneys that directly contributes to heart failure, explaining why heart-related complications are the leading cause of death for the over 35 million Americans living wiht chronic kidney disease.This discovery offers potential for earlier diagnosis and targeted treatments.
the Role of Cardiac Fibrosis
Damaged kidneys release a substance into the bloodstream that triggers cardiac fibrosis – the thickening and scarring of heart tissue – directly harming the heart. This finding explains a important portion of the elevated heart failure risk in patients with chronic kidney disease.
Definition / Direct Answer Cardiac fibrosis, induced by factors released from failing kidneys, is a key mechanism driving heart failure in patients with chronic kidney disease.
Detail The research team discovered that a specific pathway involving the protein connective tissue growth factor (CTGF) is activated in the heart consequently of this kidney-derived substance. This activation leads to the deposition of collagen and othre extracellular matrix components, stiffening the heart muscle and impairing its ability to pump effectively. The study focused on understanding the molecular mechanisms linking kidney dysfunction to heart damage.
Example or Evidence In experiments, researchers observed that blocking CTGF activity in mice with kidney disease substantially reduced cardiac fibrosis and improved heart function. UVA Health News Release details these findings, published January 16, 2024.
Prevalence of chronic Kidney Disease in the U.S.
Chronic kidney disease (CKD) is a widespread health issue, affecting a significant portion of the U.S. population. Early detection and management are crucial due to its link with cardiovascular complications.
Definition / direct Answer More than 1 in 7 American adults, approximately 35 million people, have chronic kidney disease.
Detail The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reports that CKD is especially prevalent among individuals with diabetes, high blood pressure, and a family history of kidney disease. Manny people with CKD are unaware they have the condition in its early stages, as symptoms often don’t appear until significant kidney damage has occurred.
Example or evidence According to the Centers for Disease Control and Prevention (CDC), in 2021, approximately 808,000 Americans were receiving dialysis for end-stage renal disease (ESRD), the final stage of CKD.
Implications for Early Detection and Treatment
This research highlights the importance of proactive screening and intervention for individuals with chronic kidney disease to mitigate the risk of heart failure.
Definition / Direct Answer Identifying patients at risk for heart failure earlier, through understanding the link between kidney damage and cardiac fibrosis, can enable earlier treatment and improved outcomes.
Detail Uta Erdbrügger, MD, emphasizes that both kidney and heart disease often progress silently, making early detection challenging. The discovery of this kidney-heart connection provides a potential biomarker for identifying high-risk patients and tailoring treatment strategies.Future research will focus on developing therapies that specifically target the CTGF pathway to prevent or slow the progression of cardiac fibrosis.
Example or Evidence Researchers are exploring potential therapeutic interventions, including medications that block CTGF activity, to prevent or reverse cardiac fibrosis in patients with chronic kidney disease. Mount Sinai Newsroom reported on the potential for these therapies on January 16, 20